Phosphorus Containing Patents (Class 514/48)
  • Patent number: 7812000
    Abstract: The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers of the invention comprise at least two oligonucleotides linked at their 3? ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunostimulatory oligonucleotide and having an accessible 5? end.
    Type: Grant
    Filed: October 3, 2007
    Date of Patent: October 12, 2010
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Sudhir Agrawal, Ekambar R. Kandimalla, Dong Yu, Lakshmi Bhagat
  • Patent number: 7807653
    Abstract: The present invention relates to nucleoside diphosphate mimics and nucleoside triphosphate mimics, which contain diphosphate or triphosphate moiety mimics and optionally sugar-modifications and/or base-modifications. The nucleotide mimics of the present invention, in a form of a pharmaceutically acceptable salt, a pharmaceutically acceptable prodrug, or a pharmaceutical formulation, are useful as antiviral, antimicrobial, and anticancer agents. The present invention provides a method for the treatment of viral infections, microbial infections, and proliferative disorders. The present invention also relates to pharmaceutical compositions comprising the compounds of the present invention optionally in combination with other pharmaceutically active agents.
    Type: Grant
    Filed: June 14, 2007
    Date of Patent: October 5, 2010
    Assignee: Biota Scientific Management Pty Ltd
    Inventors: Phillip D. Cook, Guangyi Wang, Thomas W. Bruice, Nicholas A. Boyle, Janet M. Leeds, Jennifer L. Brooks, Marija Prhavc, Maria Eugenia Ariza, Patrick C. Fagan, Yi Jin, Vivek K. Rajwanshi, Kathleen D. Tucker
  • Publication number: 20100222292
    Abstract: The invention relates to methods for transdifferentiation of body tissues which can be used to generate specific cell types needed for regenerating organs or body parts, following cellular degeneration, injury or amputation. The present invention also describes the use of tissue transdifferentiation for treating cancer and autoimmune diseases.
    Type: Application
    Filed: May 7, 2010
    Publication date: September 2, 2010
    Inventor: Steven Baranowitz
  • Publication number: 20100204162
    Abstract: The present invention provides a compound which is an inhibitor of sphingolipid biosynthesis for use in the treatment of a disease which has a secondary Niemann-Pick type C disease like cellular phenotype.
    Type: Application
    Filed: June 26, 2008
    Publication date: August 12, 2010
    Inventors: Mary Frances Platt, Emyr Lloyd-Evans, Forbes Dennison Porter
  • Patent number: 7772206
    Abstract: This invention relates to methods of treating or preventing an autoimmune disorder comprising the administration of clofarabine or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, prodrug or metabolite thereof to a patient in need of such treatment. The invention further relates to methods of treating or preventing an autoimmune disorder comprising the administration of clofarabine or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, prodrug or metabolite thereof and an additional therapeutic agent to a patient in need of such treatment.
    Type: Grant
    Filed: February 27, 2009
    Date of Patent: August 10, 2010
    Assignee: Genzyme Corporation
    Inventors: Christopher B. Wood, Stuart W. Smith
  • Publication number: 20100173013
    Abstract: The present application is generally directed to compounds, compositions and methods of combination therapy for the treatment of neoplastic disorders.
    Type: Application
    Filed: January 7, 2010
    Publication date: July 8, 2010
    Inventors: Denis Drygin, Kenna Anderes, Caroline B. Ho, Joshua R. Bliesath, Christopher B. Proffitt, Sean O'Brien, William G. Rice
  • Patent number: 7749975
    Abstract: The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers of the invention comprise at least two oligonucleotides linked at their 3? ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunostimulatory oligonucleotide and having an accessible 5? end.
    Type: Grant
    Filed: July 1, 2005
    Date of Patent: July 6, 2010
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Sudhir Agrawal, Ekambar R. Kandimalla, Dong Yu, Lakshmi Bhagat
  • Publication number: 20100136136
    Abstract: This invention relates to the field of protein tyrosine kinases and inhibitors thereof. In particular, the invention relates to inhibitors of JAK-2, pharmaceutical compositions of the compounds for inhibiting JAK-2, methods of inhibiting JAK-2 in a cell, comprising contacting a cell in which inhibition of JAK-2 is desired with a compound or pharmaceutical composition comprising a compound according to the invention. The also comprises methods of treating a disease or condition that involves JAK-2 comprising administering to a patient a pharmaceutical composition comprising a compound according to the invention.
    Type: Application
    Filed: September 28, 2007
    Publication date: June 3, 2010
    Applicant: EXELIXIS, INC.
    Inventors: Adam Antoni Galan, Jeff Chen, Hongwang Du, Timothy Forsyth, Tai Phat Huynh, Henry William Beecroft Johnson, Patrick Kearney, James W. Leahy, Matthew Sangyup Lee, Grace Mann, Brian Hugh Ridgway, Craig Stacy Takeuchi, Peiwen Zhou
  • Publication number: 20100119479
    Abstract: Disclosed herein are compounds represented by a formula: Therapeutic methods, compositions, medicaments, and dosage forms related thereto are also disclosed.
    Type: Application
    Filed: October 14, 2009
    Publication date: May 13, 2010
    Applicant: INTERMUNE, INC.
    Inventors: BRAD BUCKMAN, VLADIMIR SEREBRYANY, SCOTT SEIWERT, LEONID BEIGELMAN, ANTITSA STOYCHEVA
  • Patent number: 7709449
    Abstract: The invention provides compounds capable of treating against hepatitis infections, particularly hepatitis B viral infections. Compounds of the invention are nucleic acid-based and preferably comprise 2, 3, 4, 5 or 6 nucleoside units.
    Type: Grant
    Filed: July 10, 2007
    Date of Patent: May 4, 2010
    Assignee: Migenix, Inc.
    Inventors: Radhakrishnan P. Iyer, Yi Jin, Arlene Roland, Wenqiang Zhou
  • Publication number: 20100104532
    Abstract: The invention provides unsaturated phosphonates of Formula I or a tautomer or pharmaceutically accepatble salt thereof, as described herein, as well as pharmaceutical compositions comprising the compounds, and therapeutic methods comprising administering the compounds. The compounds have anti-viral properties and are useful for treating viral infections (e.g. HCV) in animals (e.g. humans).
    Type: Application
    Filed: February 8, 2008
    Publication date: April 29, 2010
    Applicant: GILEAD SCIENCES, INC.
    Inventors: James M. Chen, Alan X. Huang, Richard L. Mackman, Jay Parrish, Jason K. Perry, Oliver L. Saunders, David Sperandio
  • Publication number: 20100099643
    Abstract: Disclosed are polycyclic polyether compounds of formula I and pharmaceutical compositions comprising such compounds. wherein R, OR1, and R2 are as defined herein. Also disclosed are methods of regulating mucus clearance in a cell, and methods of treating decreased mucus clearance or mucociliary dysfunction.
    Type: Application
    Filed: December 22, 2009
    Publication date: April 22, 2010
    Inventors: Daniel G. Baden, William M. Abraham, Andrea J. Bourdelais, Sophie Michelliza
  • Patent number: 7700567
    Abstract: Oligonucleotide analogues are provided that incorporate 5-aza-cytosine in the oligonucleotide sequence, e.g., in the form of 5-aza-2?-deoxycytidine (decitabine) or 5-aza-cytidine. In particular, oligonucleotide analogues rich in decitabine-deoxyguanosine islets (DpG and GpD) are provided to target the CpG islets in the human genome, especially in the promoter regions of genes susceptible to aberrant hypermethylation. Such analogues can be used for modulation of DNA methylation, such as effective inhibition of methylation of cytosine at the C-5 position. Methods for synthesizing these oligonucleotide analogues and for modulating nucleic acid methylation are provided. Also provided are phosphoramidite building blocks for synthesizing the oligonucleotide analogues, methods for synthesizing, formulating and administering these compounds or compositions to treat conditions, such as cancer and hematological disorders.
    Type: Grant
    Filed: September 29, 2005
    Date of Patent: April 20, 2010
    Assignee: Supergen, Inc.
    Inventors: Pasit Phiasivongsa, Sanjeev Redkar
  • Patent number: 7700576
    Abstract: Novel pharmaceutical compositions which contain one of the reverse transcriptase inhibitors, viz., Zidovudine, Lamivudine or Stavudine in clinically efficacious amount and Meldonium as well as pharmaceutically applicable excipients. It has been proved that inclusion of Meldonium in these pharmaceutical compositions essentially diminishes the cardio- and neuro-toxicity of the reverse transcriptase inhibitor.
    Type: Grant
    Filed: August 8, 2006
    Date of Patent: April 20, 2010
    Assignee: Latvian Institute of Organic Synthesis
    Inventors: Vija Klusha, Sergejs Isajevs, Jolanta Pupure, Juris Rumaks, Valentina Gordjushina, Immanuels Taivans, Ivars Kalvinsh
  • Publication number: 20100093656
    Abstract: This invention relates to novel phosphate-modified nucleosides, and methods for producing them, being useful for the prevention or treatment of a viral infection in a mammal, and for preparing oligonucleotides by DNA/RNA polymerase-dependent amplification, e.g. PCR.
    Type: Application
    Filed: August 27, 2009
    Publication date: April 15, 2010
    Inventors: Olga ADELFINSKAYA, Piet HERDEWIJN
  • Publication number: 20100081627
    Abstract: Disclosed are polymeric compounds which are useful as prodrugs, comprising a chain of monomeric nucleosides, nucleoside analogs or abasic nucleosides, wherein at least one of the nucleosides or nucleoside analogs or a heterocyclic derivative thereof is pharmaceutically active and the nucleosides, nucleoside analogs or abasic nucleosides are linked by a phosphodiester group, a phosphorothioate group or an H—, alkyl or alkenyl phosphonate group.
    Type: Application
    Filed: October 2, 2009
    Publication date: April 1, 2010
    Applicant: RELIABLE BIOPHARMACEUTICAL, INC.
    Inventors: UmaShanker Sampath, Joseph A. Toce, Sourena Nadji
  • Publication number: 20100081628
    Abstract: Cyclic phosphate of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomers, salts (acid or basic addition salts), hydrates, solvates, or crystalline forms thereof, represented by the following structure:
    Type: Application
    Filed: June 5, 2009
    Publication date: April 1, 2010
    Applicant: PHARMASSET, INC.
    Inventors: Jinfa DU, Dhanapalan NAGARATHNAM, Ganapati REDDY PAMULAPATI, Bruce S. ROSS, Michael Joseph SOFIA
  • Publication number: 20100074850
    Abstract: The present invention relates to the field of improving the flavour of foodstuffs, beverages, tobacco products, pharmaceutics and oral care products. More particularly, the present invention provides flavour modulating substances selected from the group represented by formula (1): and edible salts thereof and edible esters thereof, which can advantageously be used for modulating the flavour of foodstuffs, beverages, tobacco products, pharmaceutics and oral care products. These flavour modulating substances can be used to impart desirable taste attributes in a wide variety of applications and products. In addition, the present flavour modulating substances are capable of modulating the taste and/or aroma impact of other, flavour imparting, substances contained within these same products, thereby improving the overall flavour quality of these products.
    Type: Application
    Filed: December 13, 2007
    Publication date: March 25, 2010
    Applicant: GIVAUDAN NEDERLAND SERVICES B.V.
    Inventors: Adri De Klerk, Marieke Baalbergen, Harry Renes, Chris Winkel
  • Publication number: 20100062995
    Abstract: Provided are methods of designing a putative inhibitor of a human 5?-methylthioadenosine phosphorylase (MTAP). Also provided are methods of inhibiting a human MTAP.
    Type: Application
    Filed: September 18, 2007
    Publication date: March 11, 2010
    Inventor: Vern L. Schramm
  • Patent number: 7666855
    Abstract: Compounds of Formula I, stereoisomers, and pharmaceutically acceptable salts or prodrugs thereof, their preparation, and their uses for the treatment of hepatitis C viral infection are described:
    Type: Grant
    Filed: October 30, 2006
    Date of Patent: February 23, 2010
    Assignee: Metabasis Therapeutics, Inc.
    Inventors: K. Raja Reddy, Mark D. Erion
  • Patent number: 7662361
    Abstract: The invention provides methods and compositions for modulating the activity of therapeutic agents for the treatment of a cancer by administering one or more agents that (either alone or in combination) induces telomere damage and inhibits telomerase activity in the cancer cell. The method initially uses, e.g., a telomere damage-inducing agent such as paclitaxel, and a telomerase inhibitory agent such as AZT. The invention also provides methods for identifying other agents with telomere damage-inducing activity and/or telomerase inhibitory activity (as well as and compositions having such activity), for use in the treatment of cancer.
    Type: Grant
    Filed: February 2, 2006
    Date of Patent: February 16, 2010
    Inventors: Jessie L.-S. Au, M. Guillaume Wientjes
  • Publication number: 20100022467
    Abstract: The invention is related to phosphorus substituted anti-cancer compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: September 2, 2008
    Publication date: January 28, 2010
    Inventors: Constantine G. Boojamra, Carina Cannizzaro, James M. Chen, Xiaowu Chen, Aesop Cho, Lee S. Chong, Maria Fardis, Alan X. Huang, Choung U. Kim, Thorsten Kirschberg, Steven Krawczyk, Christopher P. Lee, Kuei-Ying Lin, Richard L. Mackman, David Y. Markevitch, Peter H. Nelson, David A. Oare, Vidya K. Prasad, Hyung-Jung Pyun, Adrian S. Ray, Sundaramoorthi Swaminathan, William J. Watkins, Jennifer R. Zhang, Lijun Zhang
  • Publication number: 20100016252
    Abstract: Disclosed are Mannich base N-oxides of drugs containing acidic N—H groups. Pharmaceutical compositions comprising a therapeutically effective amount of Mannich base N-oxides, or a N-oxide rearrangement product, pharmaceutically acceptable salt or prodrug thereof, are also disclosed. Further, disclosed are methods of using the compounds, alone or in combination with one or more other active agents or treatments.
    Type: Application
    Filed: September 21, 2009
    Publication date: January 21, 2010
    Applicant: State of Oregon Acting By and Through The Oregon State Board of Higher Education On Behalf of The U
    Inventors: John F.W. Keana, Paul Westberg, John Curd, Alshad S. Lalani
  • Publication number: 20100016251
    Abstract: Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.
    Type: Application
    Filed: March 21, 2008
    Publication date: January 21, 2010
    Applicant: PHARMASSET, INC.
    Inventors: MICHAEL JOSEPH SOFIA, JINFA DU, PEIYUAN WANG, DHANAPALAN NAGARATHNAM
  • Publication number: 20100016250
    Abstract: The present invention provides TLR9 agonists comprising, as an active ingredient, a compound represented by formula (I): (wherein a represents 0 or 1; n represents an integer of 0 to 2; m represents an integer of 0 to 5; X1 and X2 each independently represent a hydrogen atom or hydroxy; Y represents an oxygen atom or a sulfur atom; -Q1-represents —O— or the like; -Q2- represents —O— or the like; -Z- represents —O— or the like; R1, R3 and R4 each independently represent hydroxy or the like; R2 and R5 each independently represent a hydrogen atom, hydroxy or the like; and A represents 6-aminopurin-9-yl or the like) or a pharmaceutically acceptable salt thereof, and the like.
    Type: Application
    Filed: April 13, 2007
    Publication date: January 21, 2010
    Applicant: KYOWA HAKKO KIRIN CO., LTD.
    Inventors: Hiroyuki Nagata, Michio Ichimura, Rieko Nakatsu, Shun-Ichi Ikeda, Ayako Kawabata, Toshio Ota, Masayuki Abe, Michio Takashima, Makoto Suzuki
  • Patent number: 7648967
    Abstract: The present invention relates to methods of treating viral disease using mutagenic nucleoside analogs. In particular, the invention provides isoguanosine nucleosides and derivatives thereof as well a method of increasing the mutation rate of a virus such as bovine viral diarrhea virus (BVDV) and hepatitis C virus (HCV).
    Type: Grant
    Filed: February 13, 2006
    Date of Patent: January 19, 2010
    Assignee: Koronis Pharmaceuticals, Incorporated
    Inventors: Ling Li, Alexander Gall, Richard Daifuku
  • Publication number: 20100004161
    Abstract: The present invention relates to an in vitro method of assessing the sensitivity of a subject to a treatment of cancer, which method comprises detecting the presence of a mutated Toll Like Receptor 4 (TLR4) nucleic acid or an abnormal TLR4 protein expression or activity in a sample from the subject, the presence of said mutated TLR4 nucleic acid or abnormal TLR4 expression or activity being indicative of a resistance to said treatment. The invention further provides compounds for treating or preventing a cancer in a subject having a mutated TLR4 nucleic acid or an abnormal TLR4 protein expression or activity.
    Type: Application
    Filed: July 17, 2007
    Publication date: January 7, 2010
    Inventors: Lionel Apetoh, Guido Kroemer, Laurence Zitvogel
  • Patent number: 7635690
    Abstract: The present invention discloses a method for treating HIV that includes administering ?-D-D4FC or its pharmaceutically acceptable salt or prodrug to a human in need of therapy in combination or alternation with a drug that induces a mutation in HIV-1 at a location other than the 70(K to N), 90 or the 172 codons of the reverse transcriptase region. Also disclosed is a method for using ?-D-D4FC as “salvage therapy” to patients which exhibit drug resistance to other anti-HIV agents. ?-D-D4FC can be used generally as salvage therapy for any patient which exhibits resistance to a drug that induces a mutation at other than the 70(K to N), 90 or the 172 codons.
    Type: Grant
    Filed: October 3, 2006
    Date of Patent: December 22, 2009
    Assignee: Emory University
    Inventors: Raymond F. Schinazi, Jennifer L. Hammond, John W. Mellors, Dennis C. Liotta
  • Patent number: 7635689
    Abstract: 2? and/or 3? prodrugs of 1?, 2?, 3? or 4?-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are described. Methods and uses are also provided that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.
    Type: Grant
    Filed: December 6, 2004
    Date of Patent: December 22, 2009
    Assignees: Idenix Pharmaceuticals, Inc., Universita Degli Studi di Cagliari, Centre National de la Recherche Scientifique, L'Universite Montpellier II
    Inventors: Paola LaColla, Richard Storer, Gilles Gosselin, Jean-Pierre Sommadossi
  • Patent number: 7632821
    Abstract: The present invention provides ribonucleoside 2?,3?-cyclic acetals of structural formula I which are precursors or prodrugs of inhibitors of RNA-dependent RNA viral polymerase. These compounds are precursors of inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as precursors or prodrugs of inhibitors of hepatitis C virus (HCV) NS5B polymerase, as precursors or prodrugs of inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such ribonucleoside 2?,3?-cyclic acetals alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection.
    Type: Grant
    Filed: August 4, 2006
    Date of Patent: December 15, 2009
    Assignee: Merck & Co., Inc.
    Inventors: Gabor Butora, Kenneth Alan Koeplinger, Malcolm MacCoss, Daniel R. McMasters, David B. Olsen, Lihu Yang
  • Publication number: 20090306007
    Abstract: The invention provides a compound of formula (I), wherein R1-R6 and X have any of the values described, as well as pharmaceutical compositions comprising such compounds and therapeutic methods comprising the administration of such compounds.
    Type: Application
    Filed: December 8, 2005
    Publication date: December 10, 2009
    Applicant: Regents of the University of Minnesota
    Inventor: Carston R. Wagner
  • Patent number: 7625872
    Abstract: The invention provides immunomodulatory compounds and methods for immunomodulation of cells and individuals using the immunomodulatory compounds.
    Type: Grant
    Filed: December 17, 2003
    Date of Patent: December 1, 2009
    Assignee: Dynavax Technologies Corporation
    Inventor: Karen L. Fearon
  • Patent number: 7625876
    Abstract: The present invention provides a method of optimizing therapeutic efficacy and reducing toxicity associated with 6-mercaptopurine drug treatment of an immune-mediated gastrointestinal disorder such as inflammatory bowel disease. The method of the invention includes the step of determining the level of one or more 6-mercaptopurine metabolites in the patient having an immune-mediated gastrointestinal disorder.
    Type: Grant
    Filed: August 20, 2007
    Date of Patent: December 1, 2009
    Assignee: Hopital-Sainte-Justine
    Inventors: Ernest G. Seidman, Yves Theoret
  • Patent number: 7625875
    Abstract: 2? and 3?-Prodrugs of 1?, 2?, 3? or 4?-branched ?-D or ?-L nucleosides, or their pharmaceutically acceptable salts and derivatives are described, which are useful in the prevention and treatment of Flaviviridae infections and other related conditions. These modified nucleosides provide superior results against flaviviruses and pestiviruses, including hepatitis C virus and viruses generally that replicate through an RNA dependent RNA reverse transcriptase. Compounds, compositions, methods and uses are provided for the treatment of Flaviviridae infection, including HCV infection, that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.
    Type: Grant
    Filed: December 6, 2004
    Date of Patent: December 1, 2009
    Assignees: Idenix Pharmaceuticals, Inc., Universita Degli Studi di Cagliari, Centre National de la Recherche Scientifique, L'Universite Montpellier II
    Inventors: Gilles Gosselin, Richard Storer, Paola LaColla, Jean-Pierre Sommadossi
  • Patent number: 7618949
    Abstract: The present invention provides a P2Y12 receptor antagonist compound-eluting stent, wherein the stent is coated with one or more P2Y12 receptor antagonist compounds or a pharmaceutically acceptable salt, solvate, or hydrate thereof. When the stent is placed in a narrowed or damaged arterial vessel, a therapeutically effective amount of the P2Y12 receptor antagonist compound is eluted continuously from the stent to the local environment of the stent. The P2Y12 receptor antagonist compound-eluting stents are useful in preventing thrombosis and restenosis, and are effective in inhibiting the contraction of vascular smooth muscle cells, inhibiting cell proliferation, and reducing inflammation.
    Type: Grant
    Filed: July 30, 2008
    Date of Patent: November 17, 2009
    Assignees: Inspire Pharmaceuticals, Inc., University of North Carolina at Chapel Hill
    Inventors: José L. Boyer, James G. Douglass, III, Sammy R. Shaver
  • Publication number: 20090274686
    Abstract: The present invention discloses compounds of formula (I) or (II), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit, preventing or treating abnormal cellular proliferation and/or a viral infection, particularly by HIV, HCV or HBV. Consequently, the compounds of the present invention interfere with the replication cycle of a virus and are also useful as antiviral agents, or interfere with host cellular biochemical process and are also useful as antiproliferative agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from viral infection and/or cell proliferation. The invention also relates to methods of treating a viral infection and/or cell proliferation in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: May 1, 2009
    Publication date: November 5, 2009
    Inventors: Yat Sun Or, Lu Ying, Xiaowen Peng, Ce Wang, Yao-Ling Qiu
  • Patent number: 7612047
    Abstract: The present invention relates to mononucleoside phosphate compounds that have the benefits of a dinucleotide pharmaceutical. These mononucleoside phosphates can be made from a mononucleotide that has been modified by attaching a degradation-resistant substituent on the terminal phosphate of a polyphosphate mononucleotide. By attaching this degradation-resistant substituent, the stability from degradation matches or exceeds those of certain dinucleotides. The mononucleoside phosphate compounds of the present invention are useful in preventing and treating epithelial tissue diseases or diseases or disorders associated with platelet aggregation.
    Type: Grant
    Filed: September 10, 2008
    Date of Patent: November 3, 2009
    Assignee: Inspire Pharmaceuticals, Inc.
    Inventors: James G. Douglass, III, Benjamin R. Yerxa, Sammy R. Shaver, Ward M. Peterson, Edward G. Brown, Christopher S. Crean, José L. Boyer
  • Patent number: 7608600
    Abstract: 2? and/or 3? prodrugs of 1?, 2?, 3? or 4?-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are described. Methods and uses are also provided that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.
    Type: Grant
    Filed: June 27, 2003
    Date of Patent: October 27, 2009
    Assignees: Idenix Pharmaceuticals, Inc., University of Cagliari, Centre National de la Recherche Scientifique, L'Universite Montfellier II
    Inventors: Richard Storer, Gilles Gosselin, Jean-Pierre Sommadossi, Paola LaColla
  • Patent number: 7608597
    Abstract: A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1?, 2? or 3?-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.
    Type: Grant
    Filed: June 20, 2003
    Date of Patent: October 27, 2009
    Assignees: Idenix Pharmaceuticals, Inc., Universita Degli Studi Di Cagliari
    Inventors: Jean-Pierre Sommadossi, Paulo LaColla
  • Patent number: 7608599
    Abstract: The invention provides novel nucleoside compounds of formula I wherein R1, R2a, R2b, R3, R4, R5 R6, R8a, R9 and R10 are as defined herein which are useful for the treatment of Hepatitis C Virus (HCV) mediated diseases.
    Type: Grant
    Filed: August 11, 2006
    Date of Patent: October 27, 2009
    Assignee: Roche Palo Alto LLC
    Inventors: Klaus Klumpp, Joseph Armstrong Martin, Christopher McGuigan, David Bernard Smith
  • Publication number: 20090258837
    Abstract: The invention relates to analogous compounds of 6-thioguanosine triphosphate of general formula (I). A compound of the general formula (I); wherein the dashed bond in the sugar moiety can be either single or double and wherein R1, R2, R3, R4 or R5, equal or different between each other, have general formula -(Int)m-Ter, wherein m is between 0 and 12 and Int and Ter are Internal and Terminal building blocks, wherein Int is selected from the group consisting of formula (II); and Ter is selected from the group consisting of formula (III).
    Type: Application
    Filed: July 24, 2006
    Publication date: October 15, 2009
    Inventors: Giancarlo Naccari, Sergio Baroni
  • Patent number: 7592326
    Abstract: Cycic di-GMP, or a cyclic dinucleotide analogue thereof that has the same effect as cyclic di-GMP, stimulates or enhances immune or inflammatory response in a patient or enhances the immune response to a vaccine by serving as an adjuvant.
    Type: Grant
    Filed: January 30, 2007
    Date of Patent: September 22, 2009
    Inventor: David K. R. Karaolis
  • Patent number: 7582616
    Abstract: Compounds or compositions that are inhibitors and/or ligands of nucleoside transporters; and methods of treating cancer, heart disease and stroke, as well as AIDS and other infectious diseases.
    Type: Grant
    Filed: December 31, 2003
    Date of Patent: September 1, 2009
    Assignee: Quesrema Enterprises LLC
    Inventor: John Kwesi Buolamwini
  • Publication number: 20090215716
    Abstract: An object of the present invention is to provide a novel compound that is an agonist of guanosine-3?,5?-cyclic monophosphate and has an effect of activating protein kinase G. The present invention provides 8-guanosine-3?,5?-cyclic monophosphate compound which is represented by the following formula, and a pharmaceutical composition, especially a protein kinase G activating agent, which contains the 8-guanosine-3?,5?-cyclic monophosphate compound as an active ingredient.
    Type: Application
    Filed: February 28, 2006
    Publication date: August 27, 2009
    Applicant: KUMAMOTO UNIVERSITY
    Inventors: Takaaki Akaike, Teruo Akuta
  • Patent number: 7576068
    Abstract: This invention relates to methods for treating or preventing hepatitis C virus infections in mammals using Toll-Like Receptor (TLR)7 ligands and prodrugs thereof. More particularly, this invention relates to methods of orally administering a therapeutically effective amount of one or more prodrugs of TLR7 ligands for the treatment or prevention of hepatitis C viral infection. Oral administration of these TLR7 immunomodulating ligands and prodrugs thereof to a mammal provides therapeutically effective amounts and reduced undesirable side effects.
    Type: Grant
    Filed: September 1, 2004
    Date of Patent: August 18, 2009
    Assignee: Anadys Pharmaceuticals, Inc.
    Inventor: Devron R. Averett
  • Publication number: 20090203638
    Abstract: Pharmaceutical compositions include compounds with cytokinin activity to modulate glucose and/or lipid metabolism in a mammal. Especially preferred compounds include those comprising a purine scaffold, and it is further preferred that contemplated compositions are employed to prevent and/or treat various diseases, including pre-diabetes, insulin resistance, type-2 diabetes, Syndrome X, and dyslipidemia. In still further preferred aspects, compounds with cytokinin activity are used to activate AMPK and/or Akt. Consequently, various diseases associated with dysregulation of AMPK and/or Akt may be treated using the compounds of the present inventive subject matter.
    Type: Application
    Filed: April 7, 2009
    Publication date: August 13, 2009
    Applicant: VDF FUTURECEUTICALS, INC.
    Inventors: Dusan Miljkovic, Jovan Hranisavljevic, Zbigniew Pietrzkowski
  • Publication number: 20090202470
    Abstract: The invention is related to phosphorus substituted anti-viral inhibitory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: July 26, 2005
    Publication date: August 13, 2009
    Applicant: Gilead Sciences, Inc.
    Inventors: Constantine G. Boojamra, Kuei-Ying Lin, Richard L. Mackman, David Y. Markevitch, Oleg V. Petrakosvsky, Adrian S. Ray, Lijun Zhang
  • Patent number: 7569555
    Abstract: Cycic di-GMP, or a cyclic dinucleotide analogue thereof that has the same effect as cyclic di-GMP, stimulates or enhances immune or inflammatory response in a patient or enhances the immune response to a vaccine by serving as an adjuvant. Cyclic di-GMP, or a cyclic dinucleotide analogue thereof, also has neuroprotective properties for use as a neuroprotective agent to inhibit, treat, or ameliorate the effects of injuries, diseases, disorders or conditions that result in neurodegeneration.
    Type: Grant
    Filed: March 15, 2005
    Date of Patent: August 4, 2009
    Inventor: David K. R. Karaolis
  • Patent number: 7566703
    Abstract: The invention relates to specific C-Class semi-soft CpG immunostimulatory oligonucleotides that are useful for stimulating an immune response. In particular the oligonucleotides are useful for treating allergy, such as allergic rhinitis and asthma, cancer and infectious disease, such as hepatitis B and hepatitis C.
    Type: Grant
    Filed: October 20, 2005
    Date of Patent: July 28, 2009
    Assignees: Coley Pharmaceutical Group, Inc., Coley Pharmaceutical GmbH
    Inventors: Arthur M. Krieg, Ulrike Samulowitz, Jörg Vollmer, Eugen Uhlmann
  • Patent number: 7557093
    Abstract: The invention provides a composition for promoting collagen production, and more specifically, provides a composition capable of promoting collagen production in human dermis. Further, the invention provides a method for promoting collagen production. The invention provides a composition for promoting collagen production containing a purine nucleic acid-related substance as an active ingredient as well as a composition for promoting collagen production containing a purine nucleic acid-related substance and a pyrimidine nucleic acid-related substance. The method for promoting collagen production of the invention comprises applying a purine nucleic acid-related substance alone or in combination with a pyrimidine nucleic acid-related substance to the skin.
    Type: Grant
    Filed: October 8, 2004
    Date of Patent: July 7, 2009
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Shigeo Shinohara, Mitsuaki Kawamura